Search Results 2601 – 2620 of 3231
What's New in the Guidelines
https://clinicalinfo.hiv.gov/node/9404
Coccidioidomycosis
https://clinicalinfo.hiv.gov/node/9405
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient
https://clinicalinfo.hiv.gov/node/9407
Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease
https://clinicalinfo.hiv.gov/node/9410
Tenofovir DF
https://clinicalinfo.hiv.gov/node/9411
Progressive Multifocal Leukoencephalopathy/JC Virus Infection
https://clinicalinfo.hiv.gov/node/9412
Overview
https://clinicalinfo.hiv.gov/node/9413
Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure
https://clinicalinfo.hiv.gov/node/9414
Treatment Goals
https://clinicalinfo.hiv.gov/node/9416
Syphilis
https://clinicalinfo.hiv.gov/node/9418
Giardiasis
https://clinicalinfo.hiv.gov/node/9419
Clinical and Laboratory Monitoring of Pediatric HIV Infection
https://clinicalinfo.hiv.gov/node/9421
Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents
https://clinicalinfo.hiv.gov/node/9422
Herpes Simplex Virus
https://clinicalinfo.hiv.gov/node/9424
Leishmaniasis
https://clinicalinfo.hiv.gov/node/9425
Mycobacterium tuberculosis
https://clinicalinfo.hiv.gov/node/9426
Lamivudine (Epivir, 3TC)
https://clinicalinfo.hiv.gov/node/9427
Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class
https://clinicalinfo.hiv.gov/node/9428
Human Herpesvirus-8 Disease
https://clinicalinfo.hiv.gov/node/9430
Table 6. Dosing Recommendations for Drugs Used to Treat or Prevent Opportunistic Infections that Require Dosage Adjustment in Adults With Renal Insufficiency
https://clinicalinfo.hiv.gov/node/9432